Editorial Board About Us

Sildenafil

All articles from this key word are listed below.

Volume 4, Supplement 3 Supplement

Future Strategies for Treating Erectile Dysfunction

Thomas Magee Nestor Gonzalez-Cavidad Jacob Rajfer

Erectile dysfunction Sildenafil Gene therapy Nitric Oxide Smooth muscle cells Cyclic guanosine monophosphate

Volume 4, Supplement 3 Supplement

Four-Year Review of Sildenafil Citrate

Andrew R McCullough

Sildenafil Phosphodiesterase-5 inhibitor Nitric Oxide Cyclic guanosine

Volume 5, Supplement 6 Supplement

Oral Pharmacotherapy and the Contemporary Evaluation and Management of Erectile Dysfunction

Gregory A Broderick

Erectile dysfunction Tadalafil Sildenafil Vardenafil Apomorphine

Volume 6, Number 1 Review Articles

Managing Early Ejaculation: What Does the Future Hold?

Treatment Update

Michael P O'Leary

Sildenafil Premature ejaculation Ejaculatory latency Selective serotonin

Volume 7, Supplement 8 Review Articles

Sexual Function and a-Blockers

Benign prostatic hyperplasia Lower urinary tract symptoms Sildenafil Blockers Sexual dysfunction

Volume 7, Supplement 2 Review Articles

PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy

Harin Padma-Nathan

Radical prostatectomy Erectile dysfunction Tadalafil Sildenafil Vardenafil Phosphodiesterase-5 inhibitor

Volume 9, Number 2 Review Articles

Phosphodiesterase Type 5 Inhibitors for the Treatment of Male Lower Urinary Tract Symptoms

Treatment Update

Ricardo R Gonzalez Steven A Kaplan

Both lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) and erectile dysfunction have a very high prevalence among aging men, and there is some clinical evidence that they may share a common pathophysiology. Consequently, several preliminary studies of phosphodiesterase type 5 inhibitors—sildenafil and tadalafil—have recently been conducted in men with concomitant erectile dysfunction and lower urinary tract symptoms to determine whether these agents are effective for the treatment of symptomatic BPH. These studies have demonstrated efficacy, both alone and in combination with an -blocker, in treating lower urinary tract symptoms along with sexual dysfunction. However, larger-scale randomized studies are necessary to determine long-term safety, efficacy, and cost effectiveness. [Rev Urol. 2007;9(2):73-77]

Benign prostatic hyperplasia Lower urinary tract symptoms Erectile dysfunction Tadalafil Sildenafil Phosphodiesterase type 5 inhibitors

Volume 10, Number 1 Review Articles

Impact of Phosphodiesterase Type 5 Inhibitors on Endothelial Function

Treatment Update

John P Mulhall Patrick E Teloken

It is now known that endothelial health is essential for normal erectile function, and changes in endothelial integrity or function may lead to erectile dysfunction (ED). Because phosphodiesterase type 5 (PDE-5) inhibitors have been shown to improve endothelial function, many investigators have questioned whether PDE-5 inhibition will lead to improvement in erectile function. Data from the studies reviewed in this article show that therapy with PDE-5 inhibitors results in improvement in flow-mediated dilation, nocturnal penile tumescence and rigidity, and carotid artery intima-media thickness as well as higher scores on the Sexual Health Inventory for Men, International Index of Erectile Function, Erection Function Domain, and other instruments. Further research is needed to determine whether long-term PDE-5 inhibition can reverse ED and whether use of these agents will decrease cardiovascular morbidity in high-risk populations. [Rev Urol. 2008;10(1):26-30]

Erectile dysfunction Tadalafil Sildenafil Endothelial function Phosphodiesterase type 5inhibitors

Volume 14, Number 3 Review Articles

Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

Treatment Update

Steven A Kaplan Richard K Lee Dean S Elterman Alexis E Te Bilal Chughtai

Many aging men will experience both erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), resulting in lower urinary tract symptoms (LUTS). Basic and clinical evidence suggests common pathogenic mechanisms underlying both LUTS and ED. Decreases in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway with age result in decreased levels of intracellular cGMP and calcium, leading to diminished smooth muscle relaxation of the bladder and prostate and worsening LUTS. Phosphodiesterase type 5 inhibitors as monotherapy in combination with a-blockers have shown efficacy in treating both LUTS and ED. Tadalafil has recently been approved by the US Food and Drug Administration for the treatment of LUTS secondary to BPH, with or without concomitant ED. [Rev Urol. 2012;14(3/4):79-86 doi: 10.3909/riu0559] © 2013 MedReviews®, LLC

Benign prostatic hyperplasia Lower urinary tract symptoms Erectile dysfunction Phosphodiesterase inhibitors Tadalafil Sildenafil Vardenafil